Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash from Discontinued Operations (2023 - 2025)

Legend Biotech (LEGN) posted Cash from Discontinued Operations of 106286000.0 for Q1 2025, down 29.49% on a QoQ basis from 82078000.0 in Q4 2024, and down 4558.31% year-over-year from 2384000.0 in Q1 2024.

Legend Biotech (LEGN) has 3 years of Cash from Discontinued Operations data on file, last reported at 106286000.0 in Q1 2025.

  • In Q1 2025, Cash from Discontinued Operations fell 4558.31% year-over-year to 106286000.0; the TTM figure through Mar 2025 stood at 281625000.0 (changed N/A YoY), while the FY2024 annual figure was 144033000.0, up 63.38% from the prior year.
  • Cash from Discontinued Operations slipped to 106286000.0 in Q1 2025, from 82078000.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 2384000.0 in Q1 2024 and bottomed at 106286000.0 in Q1 2025.
  • A 3-year average of 70406250.0 and a median of 88861500.0 in 2023 frame the typical range for Cash from Discontinued Operations.
  • Annual changes were most pronounced in 2024 — Cash from Discontinued Operations gained 14.18% — and 2025, when it plunged 4558.31%.
  • Year by year, Cash from Discontinued Operations stood at 95645000.0 in 2023, then climbed by 14.18% to 82078000.0 in 2024, then decreased by 29.49% to 106286000.0 in 2025.
  • The last three Cash from Discontinued Operations figures came in at 106286000.0 (Q1 2025), 82078000.0 (Q4 2024), and 2384000.0 (Q1 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Revolution Medicines 32.39 Bn 32.39 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2025 -106.29 Mn
Mar 31, 2025 -106.29 Mn
Dec 31, 2024 -82.08 Mn
Dec 31, 2024 -82.08 Mn
Mar 31, 2024 2.38 Mn
Mar 31, 2024 2.38 Mn
Dec 31, 2023 -95.65 Mn
Dec 31, 2023 -95.65 Mn